Oncolytics Biotech Inc Financials
This page shows Oncolytics Biotech Inc (ONCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Oncolytics is operating as a capital-funded development business, with steady cash burn and a balance sheet that now relies on fresh financing.
Across the last two valid years, operating cash outflow stayed near-$20.1M , so the business did not materially become leaner. Because cash fell to$5.2M while financing inflow reached$14.1M , activity was maintained by new capital rather than internally generated resources.
The accounting loss widened even though research spending fell to
The balance sheet lost flexibility: current ratio slid to 1.1x and equity moved to
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Oncolytics Biotech Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Oncolytics Biotech Inc has a moderate D/E ratio of -3.00. This balance of debt and equity financing earns a leverage score of 39/100.
Oncolytics Biotech Inc's current ratio of 1.12 is below the typical benchmark, resulting in a score of 17/100. However, the company holds substantial cash reserves (85% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
Oncolytics Biotech Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Oncolytics Biotech Inc generates $0.70 in operating cash flow (-$20.1M OCF vs -$28.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Oncolytics Biotech Inc's EBITDA was -$28.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.6% from the prior year.
Oncolytics Biotech Inc reported -$28.8M in net income in fiscal year 2025. This represents a decrease of 26.2% from the prior year.
Oncolytics Biotech Inc earned $-0.30 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Cash & Balance Sheet
Oncolytics Biotech Inc generated -$20.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 0.3% from the prior year.
Oncolytics Biotech Inc held $5.2M in cash against $0 in long-term debt as of fiscal year 2025.
Oncolytics Biotech Inc had 108M shares outstanding in fiscal year 2025. This represents an increase of 35.0% from the prior year.
Margins & Returns
Capital Allocation
Oncolytics Biotech Inc invested $13.3M in research and development in fiscal year 2025. This represents a decrease of 13.8% from the prior year.
Oncolytics Biotech Inc invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 96.6% from the prior year.
ONCY Income Statement
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| R&D Expenses | $4.6M | N/A | $2.8M | N/A |
| SG&A Expenses | $4.7M | N/A | $2.2M | N/A |
| Operating Income | -$9.3M | N/A | -$5.0M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A |
| Net Income | -$9.2M | N/A | -$4.7M | N/A |
| EPS (Diluted) | $-0.08 | N/A | $-0.06 | N/A |
ONCY Balance Sheet
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|
| Total Assets | $8.2M+7.6% | $7.6M | N/A | $13.4M |
| Current Assets | $7.5M+9.4% | $6.8M | N/A | $12.4M |
| Cash & Equivalents | $5.5M+5.6% | $5.2M-51.1% | $10.6M-3.9% | $11.1M |
| Inventory | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A |
| Total Liabilities | $13.3M+16.8% | $11.4M | N/A | $10.1M |
| Current Liabilities | $5.4M-11.1% | $6.1M | N/A | $4.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Total Equity | -$5.1M-35.0% | -$3.8M-202.0% | $3.7M+12.9% | $3.3M |
| Retained Earnings | -$438.7M-2.2% | -$429.5M | N/A | -$400.7M |
ONCY Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|
| Operating Cash Flow | -$7.3M | N/A | -$4.7M | N/A |
| Capital Expenditures | $6K | N/A | $1K | N/A |
| Free Cash Flow | -$7.3M | N/A | -$4.7M | N/A |
| Investing Cash Flow | -$6K | N/A | -$1K | N/A |
| Financing Cash Flow | $7.6M | N/A | $4.2M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A |
ONCY Financial Ratios
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | -126.5% | N/A |
| Return on Assets | -113.3% | N/A | N/A | N/A |
| Current Ratio | 1.38+0.3 | 1.12 | N/A | 2.55 |
| Debt-to-Equity | -2.59+0.4 | -3.00 | N/A | 3.07 |
| FCF Margin | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$3.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
Is Oncolytics Biotech Inc profitable?
No, Oncolytics Biotech Inc (ONCY) reported a net income of -$28.8M in fiscal year 2025.
What is Oncolytics Biotech Inc's EBITDA?
Oncolytics Biotech Inc (ONCY) had EBITDA of -$28.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Oncolytics Biotech Inc's free cash flow?
Oncolytics Biotech Inc (ONCY) generated -$20.1M in free cash flow during fiscal year 2025. This represents a -0.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Oncolytics Biotech Inc's operating cash flow?
Oncolytics Biotech Inc (ONCY) generated -$20.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Oncolytics Biotech Inc's total assets?
Oncolytics Biotech Inc (ONCY) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Oncolytics Biotech Inc's capital expenditures?
Oncolytics Biotech Inc (ONCY) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Oncolytics Biotech Inc spend on research and development?
Oncolytics Biotech Inc (ONCY) invested $13.3M in research and development during fiscal year 2025.
What is Oncolytics Biotech Inc's current ratio?
Oncolytics Biotech Inc (ONCY) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.
What is Oncolytics Biotech Inc's debt-to-equity ratio?
Oncolytics Biotech Inc (ONCY) had a debt-to-equity ratio of -3.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Oncolytics Biotech Inc's return on assets (ROA)?
Oncolytics Biotech Inc (ONCY) had a return on assets of -379.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Oncolytics Biotech Inc's cash runway?
Based on fiscal year 2025 data, Oncolytics Biotech Inc (ONCY) had $5.2M in cash against an annual operating cash burn of $20.1M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Oncolytics Biotech Inc's debt-to-equity ratio negative or unusual?
Oncolytics Biotech Inc (ONCY) has negative shareholder equity of -$3.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Oncolytics Biotech Inc's Piotroski F-Score?
Oncolytics Biotech Inc (ONCY) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Oncolytics Biotech Inc's earnings high quality?
Oncolytics Biotech Inc (ONCY) has an earnings quality ratio of 0.70x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Oncolytics Biotech Inc?
Oncolytics Biotech Inc (ONCY) scores 9 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.